# EDGAR Filing Document

**Accession Number:** 0000719135
**File Stem:** 0001437749-26-001048
**Filing Date:** 2026-1
**Character Count:** 13002
**Document Hash:** e733b5e4f9c574dd66ef3d0afb7b9b19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-001048.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001437749-26-001048

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20260112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apyx Medical Corp
- **CENTRAL INDEX KEY:** 0000719135
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112644611
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31885
- **FILM NUMBER:** 26524742

**BUSINESS ADDRESS:**
- **STREET 1:** 5115 ULMERTON ROAD
- **CITY:** CLEARWATER
- **STATE:** FL
- **ZIP:** 33760
- **BUSINESS PHONE:** 7273842323

**MAIL ADDRESS:**
- **STREET 1:** 5115 ULMERTON ROAD
- **CITY:** CLEARWATER
- **STATE:** FL
- **ZIP:** 33760

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BOVIE MEDICAL Corp
- **DATE OF NAME CHANGE:** 20150319

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BOVIE MEDICAL CORP
- **DATE OF NAME CHANGE:** 19990216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AN CON GENETICS INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? apyx20260108_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**January 12, 2026**

Date of Report (date of earliest event reported)

![apyx20240909_8kimg001.jpg](apyx20240909_8kimg001.jpg)

**APYX MEDICAL CORPORATION**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-31885** | **11-2644611** |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**5115 Ulmerton Road, Clearwater, Florida 33760**

(Address of principal executive offices, zip code)

**(727) 384-2323**

(Issuer's telephone number)

_____________________________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Class A common stock | APYX | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

**Item 2.02 Results of Operations and Financial Condition**

On January 12, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its preliminary revenue results for the fourth quarter and year ended December 31, 2025.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

**Item 9.01**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Financial Statements and Exhibits**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press release dated January 12, 2026](ex_905857.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 12, 2026 | **Apyx Medical Corporation** | **Apyx Medical Corporation** |
|  | By: | */s/ Matthew Hill* |
|  |  | Matthew Hill |
|  |  | Chief Financial Officer, Secretary and Treasurer |

---

## Exhibit 99.1

---

| | |
|:---|:---|
| ![logo.jpg](logo.jpg) | **EXHIBIT 99.1** |

---

**Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results**

*Surgical Aesthetics revenue increased approximately 38% year-over-year in the fourth quarter of 2025, including an increase of approximately 51% in the U.S. following the launch of AYON*

**CLEARWATER, FL** — **January 12, 2026 - Apyx Medical Corporation (Nasdaq: APYX)** (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion<sup>®</sup> and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025.

**<u>Preliminary Fourth Quarter 2025 Revenue Summary</u>:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Surgical Aesthetics revenue is expected to be in the range of approximately $16.6 to $16.8 million, representing an increase of approximately 38% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ OEM revenue is expected to be approximately $2.4 million, representing an increase of approximately 13% year-over-year.

**<u>Preliminary Full Year 2025 Revenue Summary</u>:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total revenue is expected to be in the range of approximately $52.7 to $52.9 million, representing an increase of approximately 10% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Surgical Aesthetics revenue is expected to be in the range of approximately $45.2 to $45.4 million, representing an increase of approximately 17% year-over-year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ OEM revenue is expected to be approximately $7.5 million, representing a decrease of 21% year-over-year.

**<u>Management Comments</u>:**

"We are excited by AYON's commercial launch, which delivered immediate momentum and contributed to a strong fourth quarter, including an increase of approximately 51% in revenue for our Surgical Aesthetics segment in the U.S.," said Charlie Goodwin, President and CEO of Apyx Medical Corporation. "With Renuvion and AYON now in the market, we are well-positioned to capitalize on the expected increase in aesthetic surgical procedures in the U.S. This positive industry momentum is being fueled, in part, by the adoption of GLP-1 therapies resulting in significant patient weight loss and loose and lax skin."

This press release includes Apyx Medical Corporation's preliminary revenue results for the quarter and full year ended December 31, 2025. Apyx Medical plans to release its fourth quarter and full year 2025 financial results in March 2026. Actual fourth quarter and full year 2025 revenue results are subject to completion of the Company's year-end financial closing procedures and year-end audit procedures by the Company's independent registered public accounting firm.

------

![logo.jpg](logo.jpg)

**<u>Investor Relations Contact</u>:**

Jeremy Feffer, Managing Director LifeSci Advisors

OP: 212-915-2568

jfeffer@lifesciadvisors.com

**<u>About Apyx Medical Corporation</u>:**

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people's lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion<sup>®</sup> and the AYON Body Contouring System<sup>TM</sup> in the cosmetic surgery market and J-Plasma<sup>®</sup> in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at <u>www.ApyxMedical.com.</u>

**<u>Cautionary Statement on Forward-Looking Statements</u>:**

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the "FDA"), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company's financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause the Company's actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company's ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.